Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy and tolerability of budesonide 3 mg
effervescent tablet (9 mg/day) compared to placebo for the treatment of patients with
resistant oral cGvHD.